21 results
6-K
EX-99.1
PBM
Psyence Biomedical Ltd. Warrant
30 Aug 24
Current report (foreign)
4:06pm
) with 25 years private equity experience Corporate governance and listed company experience Ex Canopy Growth CEO Africa Multiple award-winning … , the USA, and South Africa Experienced in IPOs, capital raises, M&A, regulatory, compliance and corporate governance Former Head of Financial Accounting
424B3
PBM
Psyence Biomedical Ltd. Warrant
30 Aug 24
Prospectus supplement
4:00pm
the practices of its home country, which for us is Canada, rather than the Nasdaq rules as to certain corporate governance requirements, including … of such requirements. Currently, the Company does not plan to rely on the home country practice exemption with respect to its corporate governance other
F-1
PBM
Psyence Biomedical Ltd. Warrant
19 Aug 24
Registration statement (foreign)
4:07pm
the Nasdaq rules as to certain corporate governance requirements, including the requirement that the issuer have a majority of independent directors … and certain audit committee, compensation committee and nominating and corporate governance committee requirements, the requirement to disclose third party
424B3
PBM
Psyence Biomedical Ltd. Warrant
19 Aug 24
Prospectus supplement
9:27am
follow the practices of its home country, which for us is Canada, rather than the Nasdaq rules as to certain corporate governance requirements … and corporate governance committee requirements, the requirement to disclose third party director and nominee compensation and the requirement to distribute
POS AM
PBM
Psyence Biomedical Ltd. Warrant
12 Aug 24
Prospectus update (post-effective amendment)
5:23pm
private issuer may follow the practices of its home country, which for us is Canada, rather than the Nasdaq rules as to certain corporate governance requirements … and nominating and corporate governance committee requirements, the requirement to disclose third party director and nominee compensation
F-1/A
7ivc2
6 May 24
Registration statement (foreign) (amended)
8:27pm
F-1/A
4fdciajaqe
18 Apr 24
Registration statement (foreign) (amended)
6:03am
6-K
EX-99.3
k9zvelcx
12 Mar 24
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
5:25pm
F-1
fx36 omhd3a68s
9 Feb 24
Registration statement (foreign)
4:09pm
425
EX-99.1
5w27u2y
17 Jan 24
Business combination disclosure
6:00am
424B3
n3nt6m2m
15 Nov 23
Prospectus supplement
4:28pm
F-4/A
grn5e
13 Nov 23
Registration of securities (foreign) (amended)
3:59pm
F-4/A
ypnwmq0 02y05fc
13 Nov 23
Registration of securities (foreign) (amended)
9:27am
F-4/A
EX-99.1
a2dt7zi5xm1x foq2v
3 Nov 23
Registration of securities (foreign) (amended)
6:17pm
F-4/A
acxm s0fn6
3 Nov 23
Registration of securities (foreign) (amended)
6:17pm
F-4/A
2oar yf6ja2co2kr5
16 Oct 23
Registration of securities (foreign) (amended)
5:29pm
F-4/A
kcrpobj
20 Sep 23
Registration of securities (foreign) (amended)
5:26pm